Boston Scientific Corp (BSX)vsNeuropace Inc (NPCE)
BSX
Boston Scientific Corp
$45.05
+4.82%
HEALTHCARE · Cap: $62.29B
NPCE
Neuropace Inc
$14.04
+1.23%
HEALTHCARE · Cap: $511.43M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 19524% more annual revenue ($21.00B vs $106.99M). BSX leads profitability with a 17.5% profit margin vs -17.9%. BSX earns a higher WallStSmart Score of 72/100 (B).
BSX
Strong Buy72
out of 100
Grade: B
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$45.05
$5.98 premium
Margin of Safety
-17.2%
Fair Value
$12.42
Current Price
$14.04
$1.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
17.1% revenue growth
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 40.1x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.95 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 27/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?